Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

ehealth

  • Home
  •  
  • ehealth



  • Most Read
  • Latest Comments
  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    Adherium has begun manufacturing of their FDA approved respiratory inhaler
    • News

  • Adherium submits FDA application for smart inhaler to digitise respiratory treatment
    Adherium submits FDA application for smart inhaler to digitise respiratory treatment
    • News

  • US trials confirm Analytica’s effectiveness for treating urinary incontinence remotely
    US trials confirm Analytica’s effectiveness for treating urinary incontinence remotely
    • News

  • 4D Medical commences trading on the ASX, opens at 2x IPO Price
    4D Medical commences trading on the ASX, opens at 2x IPO Price
    • News

  • 1st Group launches telehealth portal, telehealthclinics.com.au
    1st Group launches telehealth portal, telehealthclinics.com.au
    • News

  • Adherium has begun manufacturing of their FDA approved respiratory inhaler
    • News

    Adherium has begun manufacturing of their FDA approved respiratory inhaler

    5-10% of the world’s population suffer from asthma. That’s over 23 million people, 7 million of whom are children.  Whilst for some it is a minor nuisance, asthma can be a chronic and often debilitating problem and can be a precursor to numerous comorbidities. The condition causes the airways to narrow and potentially produce more

    Read More
    Public
  • US trials confirm Analytica’s effectiveness for treating urinary incontinence remotely
    • News

    US trials confirm Analytica’s effectiveness for treating urinary incontinence remotely

    Australian medtech and eHealth company Analytica (ASX: ALT), developers of PeriCoach, have had their medical device data validated by leading researchers in the United States as parity to in-clinic consultations, a boon for female sufferers of urinary incontinence located in remote regions. Analytics’s data was backed up by independent trials conducted at the University of

    Read More
    Public
  • 1st Group launches telehealth portal, telehealthclinics.com.au
    • News

    1st Group launches telehealth portal, telehealthclinics.com.au

    Already facilitating 2 million medical appointments between medical professionals and patients, health tech company 1st Group (ASX: 1ST) is set to significantly grow its network with the launch of telehealthclinics.com.au – a dedicated site for booking medical appointments to be conducted via teleconference.  Whilst COVID-19 has significantly heightened public interest in telehealth, 1st Group has

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.